biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by BearDownAZon Nov 18, 2017 3:32pm

101 Views

Post# 26990069

RE:RE:RE:RE:RE:RE:RE:RE:Sangamo and Hunter Syndrome

Furthermore, one of the most developed preclinical programs at biOasis is for treating metabolic enzyme deficiencies leading to lysosomal storage diseases. So any competing approach to treat LSDs, including gene editing, is of high relevance to biOasis. BearDownAZ

Bullboard Posts

Visionstate set to leverage success in the U.S. market